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Abstract 
 An experiment conducted to explore a histopathological comparison 
between tobramycin sulphate and amikacin sulphate, and to explore the role 
of calcium gluconate in antagonizing or reducing the main toxic side effects 
of tobramycin and amikacin like nephrotoxicity.The experiment was 
designed to study the effects of therapeutic and triple doses of tobramycin 
and amikacin alone, and with calcium gluconate in rabbits. This experiment 
lasted for one month and was divided into three periods (pretreatment period 
for 7 days, treatment period for 14 days and recovery period 7 days). The 
results showed that tobramycin and amikacin differ in their toxic effects 
potential at both therapeutic and triple doses. Tobramycin caused more 
pathological changes than that changes caused by amikacin, the main 
changes in renal tissue that caused by therapeutic dose of  tobramycin are 
hydropic swelling of renal tubular epithelial cells ,vascular congestion of 
glomeruli ,while the triple dose of tobramycin caused shedding of renal 
tubular epithelial cells, formation of hyaline casts in tubular lumina , loss of 
brush border, hydorpic swelling of renal tubular epithelial cells, foci of 
moderate to heavy mixed acute and chronic inflammatory cell infiltration (in 
form of neutrophils, lymphocytes, plasma cells and occasional eosinophil). 
Pretreatment with calcium significantly improved the study to the levels 
almost similar to that of control group for both drugs, and gave complete 
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protection from toxic effects of amikacin, and complete to partial protection 
with tobramycin accordingly with their doses. 
 
Keywords: Renal histopathological changes of Amikacin and tobramycin, 
Nephrotoxicity effect of aminoglycoside 
 
Introduction 
Aminoglycoside a group of antibacterialdrugs derived from species 
of Streptomyces; they interfere with the function of bacterial ribosome. They 
contain an inositol moiety substituted with two amino or guanidine groups 
and with one or more sugars or amino sugars. (Chambers et.al., 2007). 
Low cost and high efficacy make aminoglycoside antibiotics a 
common choice for the treatment of gram negative bacterial infections. 
Amikacin and tobramycin are effective in the treatment of many 
infections like urinary tract infection, burns, respiratory tract infection, 
gynecological infection, endocarditis and some mycobacterial infections. 
While these compounds are common and very widely used, they are not 
without serious clinical side effects such as nephrotoxicity, ototoxicity and 
neuromuscular blockade (Swan,1997).  
Aminoglycosides are nephrotoxic because a sizable proportion of the 
administered dose is retained in the epithelial cells lining the S1 and S2 
segments of the proximal tubules after glomerular filtration.  
There are abundant evidences that repeated administration of all 
aminoglycoside such as amikacin and tobramycin to experimental animals 
results in increased urinary excretion of divalent cations. Hypercalciuria is 
the most frequently reported finding (Levison&Matthew,2009). 
The aminoglycosides are bactericidal antibiotic that bind to 30S 
ribosome and inhibit bacterial protein synthesis. They are polycations, and 
their polarity is responsible of their pharmacokinetic properties shared by all 
members of this group 
 
Material and Method  
The experiments were performed on healthy local male domestic 
rabbits intermediate buck (6 - 8 months) purchased from local market in 
Sulaimani.Their weights ranged between 1.5-1.9 kg. The animals were 
allocated one week prior to the experiment. They were reared at an optimal 
room temperature ranged between 22-25°C and were exposed to artificial 
light for 12 hrs/day. 
Experimental design: -For this experiment, rabbits were divided 
randomly into nine groups, each group contain 3 rabbits (n=3). 
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Group (1): G1 included rabbits treated with distilled water according 
to body weight and at a dose level of (0.1 ml/kg/B.wt./day) subcutaneously 
(S/C) throughout all the experimental period. 
Group (2): G2 all rabbits in this group were given therapeutic dose 
of tobramycin sulphate by intramuscular route (I/M) at a dose of (5 mg /kg / 
B.wt /day). 
Group (3): G3 each rabbit in this group was pretreated 
subcutaneously S/C with therapeutic dose of calcium gluconate, and then 
injected by I/M route a therapeutic dose of tobramycin sulphate which is (5 
mg/kg/ B.wt /day) 
Group (4): G4 rabbits treated with triple dose of tobramycin sulphate 
at dose level of (15 mg/kg/B.wt /day) by I/M route. 
Group (5): G5 each rabbit in this group was pretreated 
subcutaneously S/C with therapeutic dose of calcium gluconate, and then 
injected by I/M route a triple dose of tobramycin sulphate which is (15 
mg/kg/ B.wt /day) 
Group (6): G6 rabbits were injected by I/M route with therapeutic 
dose of amikacin sulphate (15 mg / kg/B.wt /day)/day. 
Group (7):G7 given therapeutic dose of amikacin sulphate at dose 
level of (15 mg/kg/ B.wt/day) by I/M injection in to rabbits pretreated with 
therapeutic dose of calcium gluconate (22.5 mg/kg/ B.wt/day). 
Group (8): G8 rabbits treated with triple dose of amikacin sulphate 
at dose level of (45 mg/kg/B.wt /day)by I/M route. 
Group (9):G9 given triple dose of amikacin sulphate at dose level of 
(45 mg/kg/ B.wt/day) by I/M injection in to rabbits pretreated with 
therapeutic dose of calcium gluconate (22.5 mg/kg/ B.wt/day). 
 
This experiment consists of three periods:- 
A. Pretreatment Period: after the animals were allocated into the 
cages, they were kept for 7 days prior to begin the experiment for adaptation 
to the new environment.  
B. Treatment Period:all the animals of antibiotic treated groups 
injected by I/M route for the period of 14 days, twice daily, once in the 
morning and another in the evening. Calcium gluconate was injected 
subcutaneously (S/C) at therapeutic dose in combination treatment groups 
about half hour before the antibiotic injection.  
C. Recovery Period: during this period and after the stoppage of all 
treatments, the animals were scarified for preparation of histopathological 
slides from the kidneys in order to see the changes in renal tissues if present. 
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Histopathological study: -  
Tissue samples (kidneys) from rabbits were removed. The organs 
were fixed in 10% NBF (100 ml formalin (40%), 4 g sodium phosphate 
monobasic, (6.5g) sodium phosphate dibasic and (900 ml D.W)and 
processed for paraffin embedding. The histopathological sections (4-6 
Microns) were stained with haematoxylin eosin. The slides were coded and 
examined.(Luna, 1968) 
Result: 
Figure (1) (Control group) (G1):-section of renal tissue from control shows adequate 
numbers of glomeruli and renal tubules, the renal glomeruli have normal capillary loops 
with no evidence of shrinkage or swelling, and the tubules are lined by cuboidal epithelial 
cells with nice brush borders and have normal lumina with no evidence of protein cast. The 
interstitial tissue is devoid of inflammatory cells.(H&E x40) 
 
Figure 2 :- (Therapeutic dose of tobramycin) (G2):-The changes in renal tissue are noted as 
following: minimal hydropic swelling of renal tubular epithelial cells (black arrow), mild 
vascular congestion of glomeruli (curved arrow).(H&E 
x40)
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Figure (3)( Therapeutic dose of tobramycin and calcium) (G3):-the section shows renal 
tissue with histological features very close to renal tissue from controls.(H&E x40) 
Figure  4:- (Triple dose of tobramycin) (G4)The changes are marked in renal tissue in form  
of shedding of renal tubular epithelial cells, formation of hyaline casts in tubular 
lumina(black arrows), loss of brush border, hydorpic swelling of renal tubular epithelial 
cells, foci of moderate to heavy mixed acute and chornic inflammatory cell infiltration (in 
form of neutrophils, lymphocytes, plasma cells and occasional eosinophil) as indicated by 
yellow arrows.(H&E x40) 
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Figure 5:- triple dose of tobramycin and calcium (G5) tobramycin effect on renal tissue in 
rabbits treated with calcium and triple dose tobramycin, The sections of renal tissue is very 
much the same as the ones taken from control group (H&E x40). 
Figure 6:- Amikacin therapeutic dose (G6) section of renal tissue shows minimal and focal 
hydropic swelling of tubular epithelial cells (black arrow)(H&E x 40). 
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Figure 7:- Amikacin therapeutic dose with calcium (G7):-The sections look very much 
similar to those of control group which indicates protective effect of calcium in preventing 
harmful effects of Amikacin on renal tissue.(H&E x40) 
 
 
Figure 8:- Amikacin triple dose (G8):-the section shows vacuolar degeneration of renal 
tubular epithelial cells (black arrows), with few cells falling away into lumen and mild 
blurring of brush border (yellow arrows). The changes are milder than those of rabbits 
treated with similar doses of tobramycin(H&E x40). 
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Figure 9:- Amikacin triple dose and Calcium (G9):-Renal tissue does not shows any of the 
changes that were seen in group treated with Amikacin alone. In fact the sections are very 
similar to those of control group (H&E x40). 
 
Discussion 
The results showed that tobramycin and amikacin differ in their toxic 
effects potential at both therapeutic and triple doses. Tobramycin caused 
more pathological changes than that changes caused by amikacin. 
Pretreatment with calcium significantly improved the study to the levels 
almost similar to that of control group for both drugs, and gave complete 
protection from toxic effects of amikacin, and complete to partial protection 
with tobramycin accordingly with their doses. Our results were in agreement 
with other studies done by (AL-Hamiree, 1997&Obid, 1999) 
In studies carried out by (Rose& Zalenzik, 1999) (Ali, 2003) 
Confirmed the ameliorate effect of oral CaCO3 (0.5 or 1.0 g/kg/B.wt) on the 
histological and biochemical changes induced by aminoglycosides 
nephrotoxicity in rats. It is suggested that high doses of tobramycin and 
amikacin cause calcium wasting and that calcium loading increased the 
delivery of ions to the kidney and prevented the binding of aminoglycoside 
to the brush border membrane, because it is suggested that the interaction 
between aminoglycoside and calcium in the kidney is due to the competition 
of these compounds for binding to nephrotic brush border membrane. 
Recently, it has been suggested that the major pathway responsible 
for renal uptake and accumulation of aminoglycoside is via megalin (a 
specific endocytic receptor and it is expressed in the renal tubule epithelium 
and inner ear epithelium); it is possibly responsible for the selective uptake 
and toxicity of aminoglycoside by these cells, therefore it was proposed that 
megalin could be considered a unique target for the prevention of 
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nephrotoxicity ,The ligands binding to Megalin represent a variety of classes 
including calcium (Giapros&Andronikou, 2004). 
The administration of aminoglycosides may induce the increase in 
urinary excretion of endogenous megalin ligands like calcium due to calcium 
competition with aminoglycosides for the binding to megalin.(Weiner 
et.al.,1997) 
When a drug is bound to megalin, the aminoglycoside – megalin 
complex is transported inside  the  cell  and joins to lysosomes which are the 
main target, since it contains 10-27% acidic phospholipids 
(phosphotidylinositol) where it cause progressive deposition  of polar lipid 
forming so called myeloid body. Additionally, several other changes 
occurred in the organelles and enzymes, resulting in a decrease in Na-K-
ATPase, adenylcyclase, mitochondrial function, ATP production, protein 
synthesis, solute reabsorption and over all cellular function (March et.al 
,1983). 
Amikacin shows reduced levels of binding to megalin and acidic 
phospholipids with a lesser inhibitory potency toward lysosomal 
phospholipase, due to some modification in the structure of amikacin by 
substitution of the amino functional group with an acyl side chain. This 
feature had been proved to cause less renal changes. 
In a study carried out by(Viotteet.al.,1983) they demonstrated that the 
number of cationic amino group (NH3) in the structure of aminoglycosides 
appear to be an important determinant of nephrotoxicity. Thus, neomycin has 
(6) molecule producing the most renal injury. Amikacin has (4) molecule, 
and so produces the least renal injury .Gentamicin and tobramycin have (5) 
molecule, therefore produce the intermediate level of changes in the renal 
tissues. These structural and kinetic differences may add to discuss 
differences in toxic potency between tobramycin and amikacin. 
The structural differences and rate of renal paranchymal 
accumulation between amikacin and tobramycin may contribute to 
interpretate nephrotoxic effect according to the dose used. 
In a study carried out (Yang et.al,1994) they used  the erythrocyte 
membrane model to rank the capacity of the aminoglycosides to impair 
phosphoinositide metabolism as follows neomycin > gentamicin > 
tobramycin > amikacin. The low intrinsic nephrotoxicity of amikacin 
reported by(Brionet.al.,1985) is in agreement with the results obtained by 
(Reyonalds et.al., 1997) who on the basis of the ultra-structural and 
biochemical alteration observed in rats, gave the following decreasing order 
of toxicity gentamicin >netilimicin>tobramycin 
>amikacin.(Giapros&Andronikou, 2004).suggested that aminoglycoside has 
an effect on the function of mitochondria and encourages the formation of 
reactive oxygen species and lipid peroxidation of the membrane lipid, 
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protein denaturation and DNA damage. The presence of evidence is linked to 
the fact that these agents inhibit the synthesis of phospholipase A2 and 
glutathione and some previously tested antioxidant agents like defroxamine, 
Vitamin C, and Vitamin E.  These agents can reduce renal injuries cause by 
AGs these approaches could not be translated in to clinical application due to 
a lack of efficacy and /or intrinsic toxicity. 
From this study it appears that tobramycin is more potent as 
nephrotoxic accordingly with the dose and treatment periods in rabbits while 
pretreatments with calcium was successfully and completely or partly 
ameliorate those toxic effects of both drugs. 
 
References: 
AL-Hamiree, J.  N. (1997):  Role of calcium in gentamicin toxicity in 
laboratory animals. Master Thesis, Collage of Veterinary Medicine, 
University of Baghdad. 
Ali, B. H. (2003): Agents ameliorating or augmenting experimental 
gentamicin Nephrotoxicity: some recent research. Food and Chem.Toxicol. 
42 (3):1447-1452. 
Brion, N.; Garoud, J. J.; Faurisson, F.; Lvey, J.C. and Debach, J. C. (1985): 
Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin and 
amikacin in humans. Antimicrob. Agents Chemother. .27(4):520-524. 
Chambers, H. F.; Hadly, K. and Jawatz, E. (2007): Aminoglycoside and 
spectinomycin ‘in Basic and clinical pharmacology. 8th Ed., Bertram G. 
Katzung. Stamford: Appleton and Lange pp: 784-792. 
Giapros, V. I.; and Andronikou, S. K. (2004): Acute effects of gentamicin on 
urinary electrolyte excretion in neonates. J. Pediatr. nephrol. 19 (3):322-325. 
Levison, Matthew E. (July 2009). "Aminoglycosides: Bacteria and 
Antibacterial Drugs". Merck Manual Professional.  
Luna LG (1968) Manual of histologic staining methods of thearmed forces 
institute of pathology, 3rd edn. McGraw-Hill, New York, NY. 
March, P.; Koutouzo, A. and Giard, A. (1983): Impairment of membrane 
phosphoinositide metabolism by aminoglycoside antibiotics, streptomycin, 
amikacin, kanamycin, dibekacine, gentamicin and neomycin. J. Pharmacol.  
Exp. Ther. 227:415-420 
Obid, K. A. (1999): The role of calcium in antagonizing side effects of 
gentamicin therapy for long period in laboratory animals, Master Thesis. 
Collage of Veterinary Medicine / University of Baghdad. 
Rose, B. D. ;andZalenzik, D.  F. (1999): Pathogenesis and prevention of 
aminoglycoside nephrotoxicity and ototoxicity. Am. J. Med. 80 (6):119-124.   
Reyonalds, A. V.; Hamilton-Miller, J. T.  andBrumfitt, W. (1997): Newer 
aminoglycoside amikacin and tobramycin: an in vitro comparison with  
kanamycin and gentamicin. British Med. J. 8 (3):778-780. 
European Scientific Journal   February 2014  edition vol.10, No.6  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
433 
Swan, S. K. (1997): Aminoglycoside nephrotoxicity. Semin.  Nephrol. Vol. 
17, No. (1):27-33 
Viotte, G.; Olier, B.; Morin, J. P. and Godin, M.  (I982): Modifications 
functional, histological, biochemical renal comparative study of dibekacine, 
gentamicin and tobramycin. Nouv. Press. Med. 11:3419-3425.  
Weiner, N. D.; Schach, J. and Au, S. (1997): Aminoglycoside antibiotics 
preferentially increase permeability in phosphoinositide containing 
membrane. Biochem .Biophys. 7(1):80-86 
Yang, C. L. and DU, X. H. (1994): Mechanism of gentamicin nephrotoxicity 
in rats and the protective effect of zink induced metallothionin synthesis. 
Nephrol. Dial. Transplant. 91(4):135-140. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
